Phase I study of erlotinib (tarceva) and temsirolimus (CCI-779) for patients with recurrent malignant gliomas (NABTC 04-02)

被引：0
|
作者：
Wen, P. Y.
Chang, S. M.
Kuhn, J.
Lamborn, K.
Robins, H. I.
Cloughesy, T.
Gilbert, M. R.
Yung, W. K. A.
Mehta, M.
DeAngelis, L. M.
Abrey, L. E.
Kesari, S.
Drappatz, J.
Lassman, A. B.
Dancey, J.
Prados, M. D.
机构：
[1] N Amer Brain Tumor Consortium, Bethesda, MD USA
[2] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA
来源：
NEURO-ONCOLOGY | 2006年 / 8卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：454 / 454
页数：1
相关论文
共 50 条
  • [1] Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04-02)
    Robins, H. I.
    Wen, P. Y.
    Chang, S. M.
    Kuhn, J.
    Lamborn, K.
    Cloughesy, T.
    Glibert, M. R.
    Yung, W. K.
    Dancey, J.
    Prados, M. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] PHASE I/II STUDY OF ERLOTINIB AND CCI-779 (TEMSIROLIMUS) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMAS (NABTC 04-02)
    Wen, Patrick
    Chang, Susan
    Kuhn, John
    Lamborn, Kathleen
    Robins, H. Ian
    Yung, Alfred
    Gilbert, Mark R.
    Cloughesy, Timothy
    Lieberman, Frank
    DeAngelis, Lisa
    Abrey, Lauren
    Drappatz, Jan
    Kesari, Santosh
    Dancey, Janet
    Prados, Michel D.
    NEURO-ONCOLOGY, 2009, 11 (02) : 232 - 232
  • [3] PHASE I/II STUDY OF ERLOTINIB AND TEMSIROLIMUS (CCI-779) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMAS (NABTC 04-02)
    Wen, Patrick
    Kuhn, John
    Chang, Susan
    Lamborn, Kathleen
    Robbins, Hi
    Cloughesy, Timothy
    Lieberman, Frank
    Mehra, Minesh
    Gilbert, Mark
    Cooper, Josh
    Drappatz, Jan
    Kesari, Santosh
    Norden, Andrew
    Groves, Morris
    Aldape, Kenneth
    Yung, W. K. Alfred
    Dancey, Janet
    Prados, Michael
    NEURO-ONCOLOGY, 2008, 10 (05) : 824 - 824
  • [4] Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02)
    Chang, S. M.
    Kuhn, J.
    Lamborn, K.
    Cloughesy, T.
    Robins, I.
    Lieberman, F.
    Yung, A.
    Dancey, J.
    Prados, M.
    Wen, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
    Wen, Patrick Y.
    Chang, Susan M.
    Lamborn, Kathleen R.
    Kuhn, John G.
    Norden, Andrew D.
    Cloughesy, Timothy F.
    Robins, H. Ian
    Lieberman, Frank S.
    Gilbert, Mark R.
    Mehta, Minesh P.
    Drappatz, Jan
    Groves, Morris D.
    Santagata, Sandro
    Ligon, Azra H.
    Yung, W. K. Alfred
    Wright, John J.
    Dancey, Janet
    Aldape, Kenneth D.
    Prados, Michael D.
    Ligon, Keith L.
    NEURO-ONCOLOGY, 2014, 16 (04) : 567 - 578
  • [6] A phase II study of temsirolimus (CCI-779) in patients with advanced leukemias.
    Yee, KWL
    Garcia-Manero, G
    Thomas, D
    Ani, FRK
    Verstovsek, S
    Andreeff, M
    Dancey, JE
    Giles, FJ
    BLOOD, 2004, 104 (11) : 214B - 214B
  • [7] A Phase II study of Temsirolimus (CCI-779) in patients with metastatic and/or recurrent endometrial cancer - NCICCTG IND 160
    Oza, A. M.
    Elit, L.
    Biagi, J.
    Panasci, L.
    Tonkin, K.
    Tsao, M.
    Dore, N.
    Dancey, J.
    Eisenhauer, E.
    Seymour, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 261 - 261
  • [8] Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
    Chang, SM
    Wen, P
    Cloughesy, T
    Greenberg, H
    Schiff, D
    Conrad, C
    Fink, K
    Robins, HI
    De Angelis, L
    Raizer, J
    Hess, K
    Aldape, K
    Lamborn, KR
    Kuhn, J
    Dancey, J
    Prados, MD
    INVESTIGATIONAL NEW DRUGS, 2005, 23 (04) : 357 - 361
  • [9] Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
    Susan M. Chang
    Patrick Wen
    Timothy Cloughesy
    Harry Greenberg
    David Schiff
    Charles Conrad
    Karen Fink
    H. Ian Robins
    Lisa De Angelis
    Jeffrey Raizer
    Kenneth Hess
    Ken Aldape
    Kathleen R. Lamborn
    John Kuhn
    Janet Dancey
    Michael D. Prados
    Investigational New Drugs, 2005, 23 : 357 - 361
  • [10] Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs
    Susan M. Chang
    John Kuhn
    Patrick Wen
    Harry Greenberg
    David Schiff
    Charles Conrad
    Karen Fink
    H. Ian Robins
    Timothy Cloughesy
    Lisa De Angelis
    Jeffrey Razier
    Kenneth Hess
    Janet Dancey
    Michael D. Prados
    Investigational New Drugs, 2004, 22 : 427 - 435
12345